# Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

> **NCT02527265** · PHASE2 · COMPLETED · sponsor: **Mannkind Corporation** · enrollment: 30 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **BIOLOGICAL:** Afrezza

## Key facts

- **NCT ID:** NCT02527265
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-28
- **Primary completion:** 2020-03-17
- **Final completion:** 2020-06-25
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02527265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02527265, "Afrezza Safety and Pharmacokinetics Study in Pediatric Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02527265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*